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Summary Current proposals for a monitoring and evaluation system in breast cancer screening programmes
focus on mortality reduction. Here emphasis is laid on the prevention of too high a number of false-positive
screening results, i.e. no subsequent demonstration of malignancy. By comparing the specificity of the
screening test, the positive predictive value and the detection rate with reference values, the screening
performance can be measured in a very early phase of the programme, even before the registration results on
interval cancers become available. The proposed average reference values for the first screening round are
99.2%, 40% and 5.4/1000, respectively. Measures specifically for the age groups 45-49, 50-59 and 60-69 will
be given, thus allowing improvements to be made if necessary.
The aim of screening for breast cancer is to reduce breast
cancer mortality. However, this effort should not lead to an
excess of false positive screening test results, which invariably
involve unnecessary diagnostic work-up. It is therefore im-
portant that screening programmes are closely monitored,
and have a good system for quality control. In such a system
one may distinguish technical aspects (apparatus and the
like), and aspects regarding the public and the participants.
Witcombe (Witcombe, 1988) even speaks of a licence or
accreditation system for radiologists. Because the anticipated
effect on breast cancer mortality will probably take 10 years
to emerge and will only occur if short term reference values
are met, quality parameters have been proposed to be eval-
uated from the very start of the programme (Day et al.,
1989). Among these are the compliance and detection rate,
disease stage distribution and interval cancer rate, to be
calculated for the initial screening, as well as for the further
screening examinations.
Here we would like to introduce additional quality para-
meters for which the values can be determined even earlier.
The emphasis is laid on potentially harmful effects, in partic-
ular the so-called false positive screening results concerning
women who have been identified by mammographic screen-
ing as suspect of having malignant lesions, and who, after
adequate diagnostic assessment, turn out to have no such
lesions.
Measures for short-term quality control
For the proposed short term quality control the only infor-
mation required is the total number of women screened, the
number of women who are suspected of having cancer
because of the initial mammography (positive screening test),
and the number of cancer patients among the positive wo-
men. With these basic data three outcome measures can be
calculated: the specificity, the positive predictive value and
the detection rate. The measures alone do not give any
valuable information, but a combination of the three do.
(1) A commonly used measure for an early indication of
the screening test performance is the predictive value of the
positive test, the PV+. This rate indicates the percentage of
breast cancer patients among women with a positive screen-
ing test result. The significance of the PV+ alone is am-
biguous, because it is dependent on the sensitivity and
specificity of the screening test and on the prevalence of
breast cancer in the detectable preclinical phase. For a con-
trol measure the dependence on the prevalence is a disadvan-
tage and unfortunately, an insight into the extent of the
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sensitivity and specificity can only be acquired after at least
two screening intervals.
(2) From a community point of view and in view of
personal and psychological considerations it is important to
evaluate the absolute and relative numbers of false-positives.
The latter numbers constitute the specificity rate. It has been
shown that it is possible to assess the specificity of a screen-
ing test even without knowledge of the number of missed
carcinomas (Morrison, 1985; Brecht & Robra, 1987). This
means that the specificity can reliably be estimated soon after
the start of the programme. The specificity rate relates to the
number of true negatives to the total number of 'non-cancer'
women. Under the rare disease assumption the specificity is
defined as:
specificity =
no. screening test negatives
no. screened women - no. screen-detected patients
(For a numerical illustration, see Figure 1).
(3) The third important measure in the short term quality
control is the detection rate. At the first screening round the
detection rate is dependent on the prevalence and the sen-
sitivity of the screening test. Expressing the detection rate as
a proportion of the expected incidence gives most infor-
mation (Day et al., 1989). However, the underlying incidence
is usually unknown, unless information about risk factors
among the screenees is gathered.
Reference values
In Table I a proposal for reference values for the specificity,
PV + and detection rate is presented. The proposals concern
modified outcomes from the Nijmegen screening programme
(Peeters et al., 1989a) and are comparable to those observed
recently in the Swedish W&E trial (Tabair et al., 1989). So
far, in both programmes a breast cancer mortality reduction
of more than 40% has been observed. The first measure to
pay attention to is the specificity. If the specificity does not
meet the reference value, improvements have to be made
irrespective of the other control outcomes. In such a screen-
ing set-up the proportion of healthy women with a positive
screening test is not acceptable.
In the Nijmegen breast cancer screening project, where
incidence rates ofinterval cancers are available, the specificity
in the first round was calculated to be 99.2% for the age
group 50-59 years. Estimated according to Brecht and
Robra (1987) the same specificity was noted with (98.8%-
-99.4%) as 95%-confidence interval. In a new screening
centre the lowest acceptable value in this age group might be
set at 99.2%, the reference value. This would allow the
screening test to mark positive a maximum of 0.8% of the
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Cancer
+ _
+ 26 202 228
Screening
test
- ?? ?? 4790
?? ?? 5018
Specificity = 96.0 %
(4790/(5018-26)]
Pv = 11.4 %
[26/228]
Detection rate = 0.52 %
(26/5018)
cancer
+_
+ 48 51 99
_ ?? ?? 8468
?? ?? 8567
Specificity = 99.4 %
(8468/ (8567-48)]
Pv = 48.5 %
(48/99]
Detection rate = 0.56 %
(48/8567]
Figure 1 Screening results of a hypothetical programme with two referral strategies.
Table I Proposed reference values for short-term quality control
Age Specificity Predictive Detection Incidence
group rate value pos. rate /1O0 years
45-49 98.9% 30% 4.5/1000 150
50-59 99.2% 40% 5.4/1000 180
60-69 99.6% 60% 6.4/1000 210
breast cancer free women. Because the quality of the mam-
mography itself has improved considerably since the
Nijmegen project started in 1975, a new screening centre
should be able to reach this reference value without difficulties.
When the specificity has reached the reference value, then
the second measure of interest is the PV+. When the PV+ of
a centre is lower than the suggested reference value, the
screening group needs to improve their screening perfor-
mance. This can for instance be realised by special training
facilities.
Creating a reference value for the detection rate is difficult.
Day et al. set the numerical value in the first screening round
at a minimum of three times the expected incidence in the
screened population (Day et al., 1989). If a higher incidence
is expected, then the reference value should be set higher
accordingly. The magnitude of the incidence can be approx-
imated, if data on the screenees' risk factor profiles are
available or can be gathered. (See also the Discussion sec-
tion). Not only the distribution of risk factors, but also the
possibility of overdiagnosis should be considered as an ex-
planation of a high detection rate. The fact that in the
Nijmegen (Peeters et al., 1989b) as well as in the Swedish
study (Tabafr et al., 1989) no overdiagnosis was claimed to be
present, does not mean that this will also apply to new
screening centres. If overdiagnosis is suspected, a revision of
the histological specimen by an independent panel of path-
ologists is strongly recommended (Beahrs & Smart, 1979).
Illustration ofquality control in a new screening centre
Suppose a new screening centre has started its programme. In
the first round women participate on their own initiative.
These women will receive an invitation for the following
screening examinations. The age of the target population is
45 years and older. The examination comprises checking the
screenee's medical history (preferably including risk factors)
and carrying out a single oblique view mammography. After
1 year the assessment strategy for the abnormality on the
initial screening program is changed on account of large
numbers of women referred to a specialist assessment team,
and of large numbers of 'tumour-negative biopsies'. In
screening parlance; in the first screening strategy the empha-
sis was laid on a high sensitivity for the detection of early
carcinomas. The second strategy loosens this attitude in
order to improve the specificity.
As can be seen in Figure 1 the specificity in Strategy 1 is
96.0%, which is lower than the weighted sum of the age-
specific reference value (99.2%, for age-distribution 2:2:1).
This is also true for the PV+ (11.4% vs 40%). From this
information it can be concluded that the number of false
positives in this screening set-up is too high and hence unac-
ceptable. The detection rate in Strategy 1 turned out to be
the same as the expected detection rate, based on the age-
specific rates in Table I. But because of the different invita-
tion set-up (own initiative vs personal invitation) it is not
known whether the age-specific detection rates would be
different. It may well be that due to selection the expected
rates in this screening population should accordingly be
higher.
As has been said, the screening strategy is changed in order
to reduce the numbers of false-positives. The outcomes of
this second strategy show that the quality of the screening
has improved indeed. The specificity has risen to 99.4%,
which is higher than the reference value. The same goes for
the predictive value: 48.5%. The conclusion can be that the
number of false positives is acceptable now. In general, both
the specificity and the sensitivity rate should be improved
simultaneously through special training facilities, and not just
by loosening the criteria for referral. The latter will only
increase the specificity, and may cause a lower sensitivity and
thus increase the number of women with a false negative
result, i.e. interval carcinomas. The higher detection rate in
Strategy 2, compared to Strategy 1 and the reference value,
reassures us that Strategy 2 will not cause a higher number of
interval carcinomas. In fact, the high detection rate in
Strategy 2 reduces the chance of a large number of false
negatives.
Applicability across programmes
A great variety of breast cancer screening programmes exists
across Great Britain, other Western European countries, the
USA and Canada. Programmes differ in screening examina-
tion, assessment procedure and screening frequency. All these
factors bear on the proposed outcome measures specificity,
predictive value and detection rate. The screening test itself
does not conclusively determine the presence or absence of
the disease, but merely sorts the screened people into test-
positives and test-negatives, i.e. women who are or are not
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mammography, although additional views may be required
to define the nature of an artefact or to compensate for a
technically inadequate mammogram. The test-positive sub-
jects then need to undergo diagnostic tests to find out
whether or not they do have breast cancer. Among these are
complete or sophisticated mammography, clinical examina-
tion, fine needle aspiration cytology, ultrasonography and
biopsy. The proposed outcome measures have been deter-
mined on the basis of the initial mammographic screening
test (applied to all women participating in the programme),
and not to the diagnostic tests assessing the abnormality
suspected of representing breast cancer. The absolute and
relative numbers of false-positive subjects are either a
reflection of 'aggressive' screening with the intention of
attaining high sensitivity, or a reflection of poor screening
performance, maybe both. When the attitude is to achieve
high sensitivity on account of large numbers of false-
positives, the proposed reference values should be adjusted,
as is done in Table II for a range of specificity rates.
When, for instance, a 95% specificity rate is considered
acceptable, then at least a 10% PV+ and a 5.8/1000 detection
rate should be observed in the programme; if not, too few
preclinical carcinomas have been detected.
One would like to know what reference values are appro-
priate in successive screening rounds. Usually, mass screening
is carried out at regular intervals, mainly of 2 or 3 years. As
regards the interval, one should not simply assume that the
specificity, PV+ and detection rate will remain constant at
successive screens. The detected cases in the next rounds
Table II Reset reference values for PV+ and detection rate according
to specificity rates considered acceptable
Acceptable
specificity PV+ Detection rate
90% 6% 5.9/1000
91% 6% 5.9/1000
92% 7% 5.9/1000
93% 8% 5.8/1000
94% 9% 5.8/1000
95% 10% 5.8/1000
96% 13% 5.7/1000
97% 16% 5.7/1000
98% 22% 5.6/1000
99% 35% 5.4/1000
994% 52% 5.3/1000
comprise new developed cases plus cases missed at the
previous screening, minus the cases that surfaced clinically
between the two screenings. As empirically the detection rate
in the first screening round was set at three times the
numerical value of the expected incidence, the detection rate
in the second screening in a programme with a 2-year screen-
ing interval is equal to 50% of the first screening detection
rate, and 65% in a programme with a 3-year interval. The
specificity will usually increase because most of the systematic
false-positive results will occur at the first screening and not
the next ones. Further, in the subsequent screening rounds
the mammograms of the previous screening examinations are
available, and the development ofmammographical signs can
be interpreted longitudinally. The PV+ tends to remain fairly
stable, unless major improvements in sensitivity as well as
specificity have taken place.
Discussion
The quality required in a screening centre must be evaluated
as soon as possible after the start of a programme. The
proposed method for short term quality control is sum-
marised in Figure 2. Only if all three control measures are
met or if the rates actually exceed the reference values, there
is no reason to make improvements.
In all populations breast cancer is a rare disease. For
example, the prevalence in the self-selected population of a
London screening centre was 14 per 1,000 (Chamberlain et
al., 1984). In the Nijmegen screening population the preva-
lence was 5.4 per 1,000. The question is to what extent
differences of this magnitude in the rare disease prevalence
will influence the control measurements. If a high risk pop-
ulation is screened the PV+ will be higher just because the
prevalence is higher. This means that the reference value
could be set higher and accordingly the proportion of false
positives would be lower. In considering the detection rate it
is of course necessary to have some knowledge of the
expected prevalence. This is possible by looking at the
prevalence of risk factors in the screening population. This is
especially important for screening high risk populations or
self-selected populations. For illustrative purposes, suppose
among 10,000 screenees 100 women will have a false positive
screening result, but the detection rate of detectable pre-
clinical disease varies: 5 per 1,000, 10 per 1,000 and 15 per
Fgow specificity ------------------------------------
L-high specificity-
1. Inmrovements necessar
Ftow detection rate- -- 2. Inrovements necessar
tow PV+
igh detection rate- 3. No reatistic pathway
tow detection rate- - 4. Imrovewnts necessary
L-high PV1
Khigh detection rate- - 5. Good, but cave overdiaonosis
Figure 2 Short term quality control: overview.
Screening-264 A.L.M. VERBEEK et al.
1,000, respectively. Then PV+ varies accordingly: 33.3%,
50% and 60%. One might be guided by published regression
coefficients generated through multivariate logistic analyses
(Alexander et al., 1988), and calculate the underlying inci-
dence rate. This rate is multplied by three to estimate the
expected detection rate in the initial screening examination. If
the observed detection rate is still too high, then the his-
tological specimen should be reviewed by an independent
panel, especially the cases of the 'borderline' category (Els-
ton, 1984).
The described method of short term quality control should
make it possible for newly started screening centres to im-
prove and optimise the screening performance at an early
stage, thus achieving a high quality screening as soon as
possible. When adjustments are necessary, a way ofachieving
this is by reviewing false positive mammograms, extra train-
ing of the radiologists and checking the technical quality of
the mammograms.
Performing short term quality control is clearly not a
substitute for evaluating the screening at a later stage. How-
ever, the presented reference values are proposals based on
data from programmes with an observed breast cancer mor-
tality reduction and with acceptable numbers offalse-positive
screening results, together with a high attendance rate:
80-90%. Of course, before starting a programme other
reference values may be chosen, presumably based on local
effectiveness considerations (Knox, 1988) or even cost-effec-
tiveness outcomes (Van der Maas et al., 1989), such as
recently presented.
Our suggested reference value of 99.2% for the specificity,
for instance, might look too high. It implies that less than
1% of the breast cancer free population is called back (refer-
red) for further diagnostic evaluation. The Forrest report
(Working Party, 1986) indicated that the referral rate, might
run up to 10% of the population. The explanation must be
the wish to achieve a nearly perfect sensitivity. This goal,
however, seems hard to attain, because a substantial number
of interval cancers are radiographically occult, even at the
time of diagnosis (Peeters et al., 1989c). Therefore, aiming to
achieve high specificity does not necessarily mean a low
sensitivity rate and a smaller breast cancer mortality reduc-
tion as a consequence.
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